Roche Drop Of Patent Case Not To Be Taken As Norm, Group Says
This article was originally published in PharmAsia News
Executive Summary
Roche's recent decision not to press on with its patents for its Herceptin (trastuzumab) breast-cancer drug delivers no signal that others would do so, according to a lobbying group representing multinational drug manufacturers.